Rocapuldencel-T

Unassigned

New Medicines

Metastatic renal cell carcinoma

Information

New molecular entity
Not Known
Argos Therapeutics

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Oct 18: Development discontinued for RCC [16].

Category

personalised dendritic cell-based immunotherapy
RCC accounts for 80-90% of kidney cancers in the UK. In 2012, there were 7,366 (4,625 male and 2,741 female) new cases of kidney cancer registered in England.
Metastatic renal cell carcinoma
Intradermal

Trial or other data

Jun 18: Argos Therapeutics terminates a PII trial due to lack of efficacy (NCT01482949) [16].


Apr 18: Argos Therapeutics discontinues the PIII ADAPT trial based on an interim analysis in which rocapuldencel-T in combination with sunitinib failed to achieve its four co-primary end points which were focused on various measures of survival [16].